Synlogic
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 6
- Market Cap
- $17.4M
- Website
- http://www.synlogictx.com
- Introduction
Synlogic, Inc. is a biopharmaceutical company which engages in the discovery and development of synthetic biotic medicines. It focuses on phenylketonuria, enteric hyperoxaluria, immuno-oncology solid tumors, inflammatory bowel disease, and vaccines and other inflammatory programs. The company was founded by James J. Collins and Timothy K. Lu on December 20, ...
Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 35
- Registration Number
- NCT05764239
- Locations
- πΊπΈ
Ann & Robert H. Lurie Children's Hospital of Chicago, Pediatrics, Chicago, Illinois, United States
πΊπΈChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
π¬πͺMedical Genetics and Laboratory Diagnostics Center, Tbilisi, Georgia
Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 31
- Registration Number
- NCT05462132
- Locations
- πΊπΈ
High Point Clinical Trials Center, High Point, North Carolina, United States
Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2023-03-17
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 11
- Registration Number
- NCT05377112
- Locations
- πΊπΈ
PPD, part of Thermo Fisher Scientific, Austin, Texas, United States
Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 106
- Registration Number
- NCT04984525
- Locations
- πΊπΈ
High Point Clinical Trials Center, High Point, North Carolina, United States
Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 77
- Registration Number
- NCT04629170
- Locations
- πΊπΈ
Genesis Clinical Research, Tampa, Florida, United States
πΊπΈPRA Health Sciences, Salt Lake City, Utah, United States
πΊπΈUrological Associates of Southern Arizona (open to remote participation), Tucson, Arizona, United States
Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With Phenylketonuria
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 20
- Registration Number
- NCT04534842
- Locations
- πΊπΈ
Excel Medical Clinical Trials, LLC, Boca Raton, Florida, United States
πΊπΈUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
πΊπΈUniversity of Texas Health Science Center at Houston, Houston, Texas, United States
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 32
- Registration Number
- NCT04167137
- Locations
- πΊπΈ
Mary Crowley Cancer Research, Dallas, Texas, United States
πΊπΈOhio State University College of Medicine, Columbus, Ohio, United States
πΊπΈUniversity of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 70
- Registration Number
- NCT03516487
- Locations
- πΊπΈ
Vanderbilt University Medical Center, Nashville, Tennessee, United States
πΊπΈChildren's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
πΊπΈBoston Children's Hospital, Boston, Massachusetts, United States
Safety, Tolerability and Pharmacodynamics of SYNB1020
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 23
- Registration Number
- NCT03447730
- Locations
- πΊπΈ
Southern California Research Center, Coronado, California, United States
πΊπΈInland Empire Liver Foundation, Rialto, California, United States
πΊπΈTexas Liver Institute, San Antonio, Texas, United States
Safety and Tolerability of SYNB1020-CP-001
- Conditions
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 52
- Registration Number
- NCT03179878
- Locations
- πΊπΈ
Parexel, Brooklyn, Maryland, United States